Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Molly Torok"'
Autor:
Debasmita Mukherjee, Mallory J. DiVincenzo, Molly Torok, Fouad Choueiry, Rahul J. Kumar, Anna Deems, Jenna L. Miller, Alice Hinton, Connor Geraghty, Jose Angel Maranon, Samuel K. Kulp, Christopher Coss, William E. Carson, Darwin L. Conwell, Phil A. Hart, Jessica L. Cooperstone, Thomas A. Mace
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Abstract Chronic pancreatitis (CP) is a fibro-inflammatory syndrome in individuals who develop persistent pathological responses to parenchymal injury or stress. Novel therapeutic or dietary interventions that could lessen inflammation in this diseas
Externí odkaz:
https://doaj.org/article/189cf0125a7b4943bdf76c48d08a9636
Autor:
Justin Thomas, Min Chen, Thomas Mace, Mitch Phelps, Molly Torok, Kriti Agrawal, Trang Vu, Dwight Owen, Alyssa Castillo, Bryan Remaily, Kyeongmin Kim, Zhiliang Xie, Samuel Kulp, Christopher Coss
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/4013942ab6b44fbc868d25bf9bf053d8
Autor:
Brooke Benner, Terence M Williams, Fouad Choueiry, Molly Torok, Kriti Agrawal, Anna Deems, Alice Hinton, Jami Shaffer, Bradley W Blaser, Anne M Noonan, Darwin L Conwell, Phil A Hart, Zobeida Cruz-Monserrate, Xue-Feng Bai, William E Carson III
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background A significant challenge to overcome in pancreatic ductal adenocarcinoma (PDAC) is the profound systemic immunosuppression that renders this disease non-responsive to immunotherapy. Our supporting data provide evidence that CD200, a regulat
Externí odkaz:
https://doaj.org/article/375dc23cd67940fa8b94d32e521b9303
Autor:
Debasmita Mukherjee, Lena Bercz, Liliana D’Alesio, Jessica Wedig, Timothy Pfau, Molly Torok, Shrina Jasani, Thomas A. Mace
Publikováno v:
Cancer Research. 82:B077-B077
Background: Pancreatic ductal adenocarcinoma (PDAC), comprising of 90% pancreatic cancer malignancies, is a highly aggressive cancer with a five-year survival rate of 10.8%. Current therapies include surgical resection and chemotherapy, which are mos
Autor:
Molly Torok, Jessica L. Cooperstone, Alice Hinton, Jenna L. Miller, Darwin L. Conwell, Rahul Kumar, Phil A. Hart, Fouad Choueiry, Debasmita Mukherjee, Samuel K. Kulp, Thomas A. Mace, Anna Deems, William E. Carson, Mallory J. DiVincenzo, Jose Angel Maranon, Connor Geraghty, Christopher C. Coss
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
Chronic pancreatitis (CP) is a fibro-inflammatory syndrome in individuals who develop persistent pathological responses to parenchymal injury or stress. Novel therapeutic or dietary interventions that could lessen inflammation in this disease could s
Publikováno v:
Immunol Lett
Activating transcription factor 4 (ATF4) is a DNA binding transcription factor belonging to the family of basic Leucine zipper proteins. ATF4 can be activated in response to multiple cellular stress signals including endoplasmic reticulum stress in t
Autor:
Samuel K. Kulp, Bryan Remaily, Thomas A. Mace, Mitch A. Phelps, Alyssa Marie M Castillo, Zhiliang Xie, Kyeongmin Kim, Min Chen, Dwight H. Owen, Christopher C. Coss, Kriti Agrawal, Trang Vu, Justin Thomas, Molly Torok
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States with 5-year survival rates below 10%. PDAC is commonly diagnosed after metastasis has occurred and treatment options are limited
Autor:
Reena Shakya, Anne M. Noonan, Kriti Agrawal, Bradley W. Blaser, Mary Dillhoff, Thomas A. Mace, Phil A. Hart, Fouad Choueiry, Brooke Benner, Darwin L. Conwell, Zobeida Cruz-Monserrate, William E. Carson, Alice Hinton, Molly Torok, Jami Shaffer, Terence M. Williams, Anna Deems, Xue-Feng Bai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundA significant challenge to overcome in pancreatic ductal adenocarcinoma (PDAC) is the profound systemic immunosuppression that renders this disease non-responsive to immunotherapy. Our supporting data provide evidence that CD200, a regulato